Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Loss-making operations ⢠Negative free cash flow CYRX has strong liquidity and gross margins, but recent operating losses, negative free cash flow, and weak earnings quality make the low headline valuation appear risky rather than clearly attractive.
Price Behavior
Key Price Behavior Insights: ⢠Strong recent rally ⢠Support holding firm ⢠Resistance test ahead Support Level: $16.31â$16.51 Resistance Level: $17.13 CYRX has rallied sharply over the last month and remains bullish above $16.31 support, but needs to clear $17.13 resistance to sustain upside.
AI Summary
CYRX is a well-funded but unproven operating-leverage bet on cell-and-gene-therapy commercialization: investors should require sustained revenue growth to translate into meaningful EBITDA and free-cash-flow improvement before treating the rally near $17.13 as durable.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Closed | +4.4% |